JD Health (6618.HK) 23Q1 - As Industry Beta Fades, the Expectation Reversal Has yet to Come
⬆ $JD Health(06618)$ - As industry beta brought by COVID-19 dividend fades away, JD Health's performance growth would slow down.The current business model cannot support high valuation, so the turning point has not yet come
Continue reading on Smartkarma:- https://www.smartkarma.com/insights/jd-health-6618-hk-23q1-as-industry-beta-fades-the-expectation-reversal-has-yet-to-come?utm_source=tiger_community
By Xinyao (Criss) Wang, Insight Provider on Smartkarma:- https://www.smartkarma.com/profiles/xinyao-criss-wang?utm_source=tiger_community
On JD Health (06618):- https://www.smartkarma.com/entities/jd-health-international-inc?utm_source=tiger_community
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
